All participants (n = 342) | |
---|---|
Sociodemographic characteristics | |
Male, n (%) | 191 (56) |
Age, mean (SD) | 67.3 (10.9) |
Age group, n (%) | |
< 70 years | 190 (56) |
≥ 70 years | 152 (44) |
Country of birth, n (%) | |
Australia | 241 (71) |
Not Australia | 91 (27) |
Smoking status, n (%) | |
Never smoked | 28 (8) |
Ex-smoker | 211 (62) |
Current smoker | 83 (24) |
Past medical history, n (%) | |
Diabetes | 53 (16) |
Renal insufficiency (needing dialysis) | 5 (2) |
Myocardial infarction | 66 (19) |
Respiratory co-morbidity (FEV1 < 66%) | 47 (14) |
Neoplasm co-morbidity | 76 (22) |
Hospital type, n (%) | |
Public | 215 (63) |
Private | 127 (37) |
Clinical characteristics | |
Lung cancer type, n (%) | |
Non-small cell lung cancer | 288 (84) |
Small cell lung cancer | 35 (10) |
Neuroendocrine | 7 (2) |
Other lung cancer | 9 (3) |
TNM staging, n (%) | |
Non-small cell lung cancer | |
Localised (I-II) | 76 (26) |
Locally advanced (III) | 87 (30) |
Metastatic (IV) | 40 (14) |
Unable to assess | 85 (30) |
Small cell lung cancer | |
Extensive | 20 (57) |
Limited | 12 (34) |
Not stated | 3 (9) |
Active lung cancer treatment, n (%) | |
Surgical resections | 173 (51) |
Chemotherapy | 168 (49) |
Radiotherapy | 99 (29) |
ECOG performance status, n (%) | |
Independent (0–1) | 206 (60) |
Assistance (2–4) | 136 (40) |